Eiger BioPharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EIGRQ research report →
Companywww.eigerbio.com
Eiger BioPharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies.
- CEO
- David Apelian
- IPO
- 2014
- Employees
- 25
- HQ
- Palo Alto, CA, US
Price Chart
Valuation
- Market Cap
- $12.59M
- P/E
- -0.17
- P/S
- 0.80
- P/B
- -0.87
- EV/EBITDA
- -0.41
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 95.09%
- Op Margin
- -455.12%
- Net Margin
- -475.26%
- ROE
- -367.00%
- ROIC
- -268.20%
Growth & Income
- Revenue
- $15.77M · 16.98%
- Net Income
- $-74,963,000 · 22.54%
- EPS
- $-50.78 · 27.19%
- Op Income
- $-71,786,000
- FCF YoY
- 10.28%
Performance & Tape
- 52W High
- $16.00
- 52W Low
- $1.10
- 50D MA
- $11.27
- 200D MA
- $6.94
- Beta
- 2.78
- Avg Volume
- 13.61K
Get TickerSpark's AI analysis on EIGRQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EIGRQ Coverage
We haven't published any research on EIGRQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EIGRQ Report →